IntelGenX Corp., which specializes in novel drug delivery using pharmaceutical grade polymeric film, will work with ATAI Life Sciences to develop both psychedelic and non-psychedelic compounds for various mental health indications.
Under the terms of the partnership agreement, IntelGenx will handle pre-development and formulation work, then provide a product prototype to ATAI for further clinical investigation. The collaborators also includes contemplation of a term sheet, upon which the two companies will enter into an exclusive, royalty-bearing license for worldwide commercialization of the resulting product.
According to an IntelGenX representative, the company specializes in developing and manufacturing oral pharmaceutical films based on its VersaFilm technology.
“We have clinical and preclinical development programs for neurodegenerative brain diseases such as Alzheimer's disease, migraine, erectile dysfunction and others. We also have a cannabis-infused oral film in development for the adult use and medical markets, and a program in animal health,” the spokesperson explained.
“Our technology has the potential for faster onset of action, better bioavailability and enhanced compliance, particularly for those who have difficulty swallowing tablets and pills,” the IntelGenx representative added. “IntelGenx provides services from analytical testing through manufacturing and operates a state-of-the-art GMP facility licensed for cannabis and controlled substances.”
During the first stages of the collaboration, the two organizations will work together on a feasibility study. After IntelGenx tackles the pre-development and formulation work, staff plan to generate a prototype that can be tested in the clinic.
“This agreement further demonstrates the utility of our VersaFilm technology platform, particularly when a convenient dosage form and fast-acting formulation are required,” explained Horst Zerbe, IntelGenx CEO. “We are looking forward to working with ATAI to develop a psychedelic-containing films for the treatment of mental health disorders, and potentially to manufacturing their clinical supply, assuming successful prototype development.”
“ATAI is dedicated to developing new treatments for individuals suffering from mental health disorders, which is crucial given the increasing prevalence of depression, anxiety and addiction,” said Florian Brand, CEO of ATAI. “IntelGenx’s film technology is very well-suited for our pharmaceutical-grade psychedelic candidates, offering ATAI the potential to deliver treatments to everyone in need of new therapeutic options.”